Stock 600521 ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Zhejiang Huahai Pharmaceutical Co., Ltd.

Equities

600521

CNE000001DL5

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 01/07/2024 am IST 		5-day change 1st Jan Change
17.11 CNY +0.35% Intraday chart for Zhejiang Huahai Pharmaceutical Co., Ltd. -4.31% +16.63%
17/06 Huahai Pharmaceutical's Subsidiary Terminates Listing Guidance MT
14/06 Zhejiang Huahai Pharmaceutical Co., Ltd.(SHSE:600521) dropped from SSE 180 Index CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Huahai Pharmaceutical's Subsidiary Terminates Listing Guidance
Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution
Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21%
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Huahai Pharmaceutical Gets Approval to Market Busulfan Injection
Zhejiang Huahai Pharmaceutical Forecasts Up to 65% Rise in Q1 Profit
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Zhejiang Huahai Pharmaceutical Gets US FDA's Nod for Pemetrexed Disodium for Injection
Correction: Huahai Pharmaceutical Gets Nod to Amend Specifications for Irbesartan Tablets
Huahai Pharmaceutical Gets Nod to Amend Spefication for Irbesartan Tablets
Zhejiang Huahai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.
Huahai Pharma Selling 1.4 Billion Yuan Shares For Capacity Expansion
Huahai Pharma to Repurchase Up to 100 Million Yuan Shares
Huahai Pharma Unit Gets FDA Nod to Trial Cancer Drug
Zhejiang Huahai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Huahai Pharma Registers Drug for Prostate Treatment
Ningbo Menovo Pharma Registers Blood Pressure Drug
Huahai Pharmaceutical Gets US FDA's Nod for Dicyclomine Hydrochloride Capsules
Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600521 Stock
  4. News Zhejiang Huahai Pharmaceutical Co., Ltd.
  5. Other languages